Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

Medical advances and better knowledge of health have contributed to increased life expectancy and a growing elderly ...

They say lightning rarely strikes twice but Kezar Life Sciences has suffered its second clinical blow in as many months.

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it ...

At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...

R327G is a topical gel treatment being analysed for diabetic foot infections. Credit: Olga Apanasenko/Shutterstock. Recce ...

Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured ...

The trial enrolled 145 individuals with baseline characteristics, such as gender and distribution of PNs, representative of the global adult NF1 patient population. Credit: TimeImage ...

Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for acute ...

AbbVie’s stock price fell over 12% after emraclidine failed to meet its primary endpoints in the company’s Phase II ...

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to treat ...